| scholarly article | Q13442814 |
| P50 | author | Michael Saag | Q6834090 |
| Jonathan Sterne | Q58298018 | ||
| Peter Reiss | Q92970863 | ||
| Ole Kirk | Q102213445 | ||
| Antiretroviral Therapy Cohort Collaboration | Q122928161 | ||
| Robert S Hogg | Q37837778 | ||
| Antonella d'Arminio Monforte | Q42206554 | ||
| P2093 | author name string | C J Smith | |
| M Murray | |||
| R Weber | |||
| M J Gill | |||
| A Justice | |||
| C Tural | |||
| D M Moore | |||
| J Rockstroh | |||
| M Bruyand | |||
| M T May | |||
| P Khaykin | |||
| R J Harris | |||
| S Abgrall | |||
| V D Lima | |||
| P2860 | cites work | Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 |
| Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection | Q28361460 | ||
| Illicit drug use and HIV-1 disease progression: a longitudinal study in the era of highly active antiretroviral therapy | Q82177447 | ||
| CD4+ count-guided interruption of antiretroviral treatment | Q29619489 | ||
| Development and validation of a prognostic model for survival time data: application to prognosis of HIV positive patients treated with antiretroviral therapy | Q30947115 | ||
| Aboriginal status is a prognostic factor for mortality among antiretroviral naïve HIV-positive individuals first initiating HAART. | Q33244605 | ||
| Natural history of HIV infection in the era of combination antiretroviral therapy | Q33876280 | ||
| Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy | Q34003391 | ||
| Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. | Q34067875 | ||
| Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. | Q34068078 | ||
| Combination antiretroviral therapy and recent declines in AIDS incidence and mortality | Q34068458 | ||
| Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies | Q34139859 | ||
| Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies | Q34228103 | ||
| Decreasing international HIV transmission: the role of expanding access to opioid agonist therapies for injection drug users | Q34389303 | ||
| Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies | Q35169664 | ||
| Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users | Q36065237 | ||
| Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies | Q36285986 | ||
| Tutorial in biostatistics: competing risks and multi-state models | Q36619509 | ||
| Importance of baseline prognostic factors with increasing time since initiation of highly active antiretroviral therapy: collaborative analysis of cohorts of HIV-1-infected patients | Q36943004 | ||
| Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection | Q39574163 | ||
| Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy | Q39727219 | ||
| Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study | Q43502968 | ||
| Early immunologic and virologic responses to highly active antiretroviral therapy and subsequent disease progression among HIV-infected injection drug users | Q43617569 | ||
| Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 × 109 cells/L | Q43689007 | ||
| Highly active antiretroviral therapy and survival in HIV-infected injection drug users. | Q43903854 | ||
| Causes of death in HIV-infected French drug users, 1995-2000 | Q44272212 | ||
| Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. | Q50908151 | ||
| Uptake of and virological response to antiretroviral therapy among HIV-infected former and current injecting drug users and persons in an opiate substitution treatment programme: the Swiss HIV Cohort Study. | Q51824964 | ||
| Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study | Q56539634 | ||
| RATES OF HIV/AIDS CARE AND ANTIRETROVIRAL THERAPY RESPONSE AMONG ACTIVE INJECTION DRUG USERS | Q57259683 | ||
| Hepatitis C coinfection is independently associated with decreased adherence to antiretroviral therapy in a population-based HIV cohort | Q57259699 | ||
| Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia | Q57259701 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | collaboration | Q1145523 |
| substance abuse | Q3184856 | ||
| anti-retroviral agent | Q50430310 | ||
| P304 | page(s) | 89-97 | |
| P577 | publication date | 2011-08-07 | |
| P1433 | published in | HIV Medicine | Q15756376 |
| P1476 | title | The effect of injecting drug use history on disease progression and death among HIV-positive individuals initiating combination antiretroviral therapy: collaborative cohort analysis | |
| P478 | volume | 13 |
| Q36650552 | Ability to Work and Employment Rates in Human Immunodeficiency Virus (HIV)-1-Infected Individuals Receiving Combination Antiretroviral Therapy: The Swiss HIV Cohort Study |
| Q36373600 | Accounting for dropout reason in longitudinal studies with nonignorable dropout |
| Q40183145 | Active injection drug-abuse offsets healthcare engagement in HIV-infected patients |
| Q40053532 | Alcohol and substance use diagnoses among HIV-positive patients receiving care in NYC clinic settings |
| Q33736040 | Cohort profile: Antiretroviral Therapy Cohort Collaboration (ART-CC). |
| Q85091957 | Drugs of abuse effects on immunity and microbial pathogenesis |
| Q33768036 | Employment predicts decreased mortality among HIV-seropositive illicit drug users in a setting of universal HIV care |
| Q44965777 | Evaluation of an innovative Medicaid health policy initiative to expand substance abuse treatment in Washington State |
| Q34984426 | HIV treatment outcomes among people who inject drugs in Victoria, Australia |
| Q55411140 | Hepatitis C coinfection adversely affects the life expectancy of people living with HIV in northwestern Poland. |
| Q27028033 | Identifying the appropriate comparison group for HIV-infected individuals |
| Q28550534 | Incidence of AIDS-Defining Opportunistic Infections and Mortality during Antiretroviral Therapy in a Cohort of Adult HIV-Infected Individuals in Hanoi, 2007-2014 |
| Q47568945 | Influence of Injection Drug Use-Related HIV Acquisition on CD4 Response to First Antiretroviral Therapy Regimen among Virally Suppressed Individuals |
| Q35864236 | Injection Drug Use and Hepatitis C as Risk Factors for Mortality in HIV-Infected Individuals: The Antiretroviral Therapy Cohort Collaboration |
| Q45781456 | Late presentation of HIV infection in the country of Georgia: 2012-2015. |
| Q40477509 | Low Non-structured Antiretroviral Therapy Interruptions in HIV-Infected Persons Who Inject Drugs Receiving Multidisciplinary Comprehensive HIV Care at an Outpatient Drug Abuse Treatment Center. |
| Q36590733 | Mechanism(s) involved in opioid drug abuse modulation of HAND |
| Q44324472 | Morbidity and mortality in HIV infection |
| Q33713778 | Mortality and causes of death among HIV-infected individuals in the country of Georgia: 1989-2012. |
| Q38651586 | Mortality in migrants living with HIV in western Europe (1997-2013): a collaborative cohort study |
| Q28551895 | Mortality, Causes of Death and Associated Factors Relate to a Large HIV Population-Based Cohort |
| Q30249677 | Overview of HIV molecular epidemiology among people who inject drugs in Europe and Asia. |
| Q64238229 | Racial Disparities in Virologic Failure and Tolerability During Firstline HIV Antiretroviral Therapy |
| Q38851684 | Reducing rates of preventable HIV/AIDS-associated mortality among people living with HIV who inject drugs |
| Q34388139 | Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: the EuroSIDA study |
| Q36321356 | Seroprevalence of Human Immunodeficiency Virus and the rising epidemic of Human Immunodeficiency Virus among injecting drug users of district Patiala |
| Q36118406 | The Effect of a Multi-Level Intervention on the Initiation of Antiretroviral Therapy (ART) among HIV-Infected Men Who Inject Drugs and Were Diagnosed Late in Thai Nguyen, Vietnam |
| Q39653268 | Triangulating Syndemic Services and Drug Treatment Policy: Improving Drug Treatment Portal Locations in Baltimore City. |
| Q33880782 | Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment. |
Search more.